Mark Exley
Chief Scientific Officer LIfT BioSciences Ltd
Mark Exley, Ph.D., is LIfT’s Chief Scientific Officer and Visiting Professor at Imperial College. He was Harvard Faculty for about 20 years and has over 40 years’ Immunology expertise. He co-founded NKT Therapeutics and MiNK Therapeutics and is former CSO of Imvax. He has co-raised $160m+, taken two biotechs to or close to IPO, published 130+ papers and serves on major journal editorial boards. Mark received his B.S. from Imperial College, MS from King’s College, and Ph.D. from the Institute of Cancer Research in London and completed his post-doctoral fellowship at the Dana Farber Cancer Institute, Boston.
Seminars
Wednesday 16th September 2026
Panel Discussion: Highlighting Strategies to Streamline Regulatory Approval Across Regulatory Agencies
2:30 pm
- Detailing the transition process between FDA, EMA and IIT clinical programs to streamline clinical development across borders
- Discussing strategies for incorporating early clinical readouts from international studies to enable faster decision making before US trial initiation
- Evaluating evolving US regulatory comfort with globally generated data to showcase how aligned global development strategies can accelerate innovation while maintaining regulatory rigor
Wednesday 16th September 2026
IMANs as an Example of Innate Cells’ Direct & Indirect Therapeutic Activity
3:30 pm
- Demonstrating innate cell types including IMANs direct therapeutic activity
- Improving and broadening IMAN activity with CARs
- Showing IMANs help CAR-T, CAR-NK and other cell therapies work when they don’t
